Evidence map›Paper›PMID 39075105›Full record

ArticleScientific reports2024

Forskolin reverses the O-GlcNAcylation dependent decrease in GABA

Shekinah Phillips, John C Chatham, Lori L McMahon

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Shekinah PhillipsDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
John C ChathamDivision of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Lori L McMahonDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. mcmahon@virginia.edu.

Funding

Consequences of Noradrenergic Degeneration in the Novel TgF344-AD Rat ModelR01AG066489 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MCMAHON, LORI LYNN · 2020 to 2024
$2.9M
UAB Neuroscience Roadmap Scholars ProgramR25NS089463 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUBIN, FARAH DOMINIQUE · 2014 to 2024
$2.7M
O-GlcNac Modulation of GABAergic TransmissionF99NS134163 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PHILLIPS, SHEKINAH · 2023 to 2024
$81k
NIA NIH HHS R01 AG066489NIA NIH HHS R01AG066489NINDS NIH HHS 1F99NS134163-01NINDS NIH HHS F99 NS134163NINDS NIH HHS R25 NS089463
6 · The paper itself

Abstract

GABAergic transmission is influenced by post-translational modifications, like phosphorylation, impacting channel conductance, allosteric modulator sensitivity, and membrane trafficking. O-GlcNAcylation is a post-translational modification involving the O-linked attachment of β-N-acetylglucosamine on serine/threonine residues. Previously we reported an acute increase in O-GlcNAcylation elicits a long-term depression of evoked GABA

Indexed as

ColforsinHippocampusReceptors, GABA-ASynapsesAnimalsInhibitory Postsynaptic PotentialsMaleNeurosteroidsPhosphorylationProtein Processing, Post-TranslationalRatsRats, Sprague-DawleySynaptic TransmissionColforsinNeurosteroidsReceptors, GABA-A

Identifiers

PMID39075105
PMCPMC11286967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.